drugset / Trial / NCT01440699

Study of Allogenic Adipose-derived Stem Cells in Crohn's Fistula

NCT01440699

Phase 1 Completed 6 enrolled Anterogen Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

Adipose-derived stem cells have properties of differentiation to various types of cells, immunomodulatory effects. adipose-derived stem cells (ASCs) show also low immunogenicity. Anterogen has developed ANTG-ASC(Autologous ASC) which has shown good efficacy and safety in Phase I and II study on the patients with Crohn's fistula. However, Crohn's patients are sometimes not fat enough to extract fat tissue for culturing ASCs. Therefore the investigators have planned to study allogenic ASCs for safety and efficacy in patients with Crohn's fistula.

Timeline

Start
2011-09
Primary completion
2012-10-11
Completion
2012-11-08

Drugs

EvaluationDrugModalityDoseRoute
Subject ALLO-ASC Cell therapy 1e+07 unknown Other
Subject ALLO-ASC Cell therapy 3e+07 unknown Other

Indications